With a mission to bring innovative products from around the world to the Canadian market, Exzell Pharma aims to provide new and effective therapeutic options to patients in areas of unmet need.
After being incorporated into Biolab in 2022, the possibilities and motivation for Exzell Pharma have increased even more to become a leading source of safe, effective and affordable healthcare products in Canada.
The acquisition of Exzell Pharma represents a major growth opportunity for both the Brazilian and Canadian markets, through the expansion of the product portfolio. The purchase of Exzell Pharma also offers a significant growth opportunity for the Biolab group, by establishing an international export platform from Canada.
Biolab’s mission to enhance well-being is supported by its expanding international presence and collaborative approach to healthcare. With a team of over 4,000 professionals and one of the largest sales forces in Brazil, Biolab fosters strong relationships with healthcare providers, conducting more than 320,000 visits annually. This extensive network underscores Biolab’s experience and solidifies its position as a trusted partner in healthcare, advancing solutions to meet patients’ evolving needs.
As part of the Biolab & Co. , Exzell Pharma benefits from the expertise, resources, and strategic vision of this dynamic organization. This collaboration enables Exzell, a proudly Canadian company, to expand its healthcare offerings across Canada, focusing on both human and animal health. With Biolab’s trust in the Canadian market and its support, Exzell is well-positioned to forge new partnerships and develop innovative products that improve quality of life and promote better health outcomes across borders.